Tvardi Therapeutics, Inc. TVRD R2KPHARMA
Company Overview
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
Why Investors Should Care
Revenue has grown at a 16.1% CAGR over the past five years.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue -66.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 16.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 16.10% |
| 1 Year: | -65.96% |
Stock Price Performance
| 1 Year: | -92.26% |
| 6 Months: | -53.22% |
| 3 Months: | -36.38% |
| 1 Month: | -0.62% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)43.10 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 16.1% over 5 years.
CONS
- Trading 95.7% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | TVRD Tvardi Therapeutics, Inc. R2KPHARMA | 1.84 | -6.81 | $17.26M | 0.00% | -127.18% | -86.96% | 16.10% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.87M | 5.06M | 5.53M | 4.38M | 5.21M | 5.79M | 4.51M | 8.09M | 5.63M | 9.27M | 112.09M | 1.94M | - | 20.27M | 4.79M | 23.00M | 10.81M | 6.17M | 6.93M | 4.87M | 2.13M | 991.00K | 2.56M | 2.57M | - | - | - |
| Operating Income | -4.72M | -5.73M | -5.01M | - | -10.99M | -13.33M | -11.77M | - | -22.32M | -9.63M | -12.96M | - | -17.12M | -17.81M | -20.47M | - | -23.13M | -24.14M | -34.43M | - | -30.00M | -25.88M | -17.02M | - | -23.56M | -30.88M | -1.12M | -27.91M | -4.47M | -23.84M | -27.65M | -32.34M | -28.90M | -29.67M | -7.18M | -5.68M | -4.35M | -8.87M | -5.94M | -7.05M |
| Net Income | -4.69M | -5.68M | -4.79M | -9.53M | -10.69M | -13.07M | -11.54M | -21.97M | -22.20M | -9.30M | -12.44M | -14.18M | -16.77M | -17.19M | -19.40M | -20.65M | -21.96M | -22.96M | -32.84M | -28.61M | -28.92M | -25.07M | -16.51M | 78.91M | -23.30M | -30.75M | -1.01M | -27.75M | -4.21M | -23.18M | -26.66M | -31.48M | -28.03M | -4.20M | -6.97M | -5.51M | -9.58M | 4.17M | -5.53M | -6.80M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.62 | -0.54 | -0.35 | 1.59 | -0.47 | -0.61 | -0.02 | -0.52 | -0.08 | -0.43 | -0.49 | -0.58 | -0.52 | -20.24 | -2.71 | -2.14 | -3.72 | -1.00 | -0.59 | -0.73 |
| R&D Expense | 3.38M | 4.68M | 5.58M | - | 8.55M | 10.76M | 9.67M | - | 20.84M | 6.96M | 9.15M | - | 13.43M | 17.00M | 22.30M | - | 23.61M | 24.36M | 35.99M | - | 33.54M | 26.11M | 21.07M | - | 19.13M | 25.23M | 15.51M | 21.27M | 19.91M | 24.69M | 24.33M | 30.31M | 25.45M | 21.96M | 6.53M | 4.79M | 3.11M | 5.81M | 3.60M | 4.91M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.19M | 11.96M | 3.18M | 3.80M | 86.00K | 911.00K | 13.47M | 19.89M | 135.08M | 23.03M | 41.87M | 20.97M | 7.14M | - |
| Operating Income | -6.24M | -237.00K | -18.07M | -25.19M | -58.40M | -59.48M | -77.38M | -111.68M | 5.38M | -89.08M | -87.53M | -121.50M | -28.11M | -26.75M |
| Net Income | -6.27M | -3.96M | -17.75M | -24.69M | -57.28M | -58.12M | -74.01M | -106.37M | 8.41M | -88.44M | -85.47M | -118.51M | -29.40M | -18.21M |
| Diluted EPS | - | - | - | - | - | - | -2.06 | -2.49 | 0.18 | -1.74 | -19.12 | -26.26 | -11.42 | -3.26 |
| R&D Expense | 4.60M | 8.69M | 15.07M | 21.22M | 49.25M | 48.52M | 75.53M | 113.82M | 107.85M | 82.70M | 91.88M | 108.51M | 23.65M | 18.01M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 18.08M | 55.93M | 110.90M | 63.83M | 97.00M | 190.82M | 232.96M | 271.16M | 247.06M | 182.24M | 125.84M | 35.20M | 32.07M |
| Total Equity | -52.06M | -58.13M | -54.08M | 51.66M | 105.04M | 50.73M | 86.78M | 133.63M | 186.71M | 249.00M | 227.52M | 158.78M | -62.06M | -91.13M | 20.95M |
| Cash & Equivalents | 4.10M | 1.12M | 12.36M | 52.66M | 15.10M | 12.09M | 9.39M | 15.08M | 18.30M | 31.68M | 13.45M | 63.74M | 51.77M | 31.61M | 20.73M |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - | - | 23.46M | 68.76M | 40.83M | 11.13M |
| Current Liabilities | - | - | 5.43M | 3.40M | 5.27M | 11.53M | 8.51M | 40.45M | 42.89M | 18.48M | 17.62M | 23.46M | 25.59M | 10.37M | 11.04M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | -47.38M | -54.83M | -22.30M | -109.22M | -5.49M | -60.09M | -78.73M | -92.08M | -18.30M | -23.50M |
| Investing Cash Flow | - | - | - | 45.02M | -36.50M | -82.82M | -30.52M | -20.27M | -4.75M | 128.71M | 43.46M | 48.74M | -10.08M |
| Financing Cash Flow | - | - | - | 123.00K | 87.92M | 110.81M | 142.60M | 39.14M | 46.61M | 311.00K | 38.15M | 27.00M | 22.70M |
| Capital Expenditure | -5.00K | -42.00K | -20.00K | -717.00K | -58.00K | -73.00K | -18.00K | -349.00K | -39.00K | -43.00K | -2.38M | -1.05M | - |
| Free Cash Flow | - | - | - | -48.10M | -54.88M | -22.37M | -109.24M | -5.84M | -60.13M | -78.77M | -94.45M | -19.35M | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | -524.0% | -2.0% | -568.8% | -662.3% | -67,907.0% | -6,529.6% | -574.5% | -561.6% | 4.0% | -386.8% | -209.1% | -579.4% | -393.8% | - |
| Net Margin % | -527.0% | -33.1% | -558.5% | -649.2% | -66,604.7% | -6,380.4% | -549.5% | -534.9% | 6.2% | -384.1% | -204.2% | -565.2% | -411.9% | - |
| ROE % | 10.8% | 7.3% | -34.3% | -23.5% | -112.9% | -67.0% | -55.4% | -57.0% | 3.4% | -38.9% | -53.8% | 191.0% | 32.3% | -87.0% |
| ROCE % | - | -1.9% | -34.4% | -23.8% | -111.7% | -67.2% | -51.5% | -58.8% | 2.1% | -38.8% | -55.1% | -121.2% | -113.2% | -127.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Slate Path Capital, LP | 5.28% | 704.12K | $1.28M |
| 2 | Vanguard Capital Management LLC | 2.58% | 344.38K | $626.77K |
| 3 | American Financial Group Inc. | 1.68% | 223.66K | $407.06K |
| 4 | UBS Group AG | 0.83% | 111.13K | $202.26K |
| 5 | Silvercrest Asset Management Group, LLC | 0.76% | 101.03K | $183.88K |
| 6 | Blackrock Inc. | 0.72% | 95.48K | $173.77K |
| 7 | Renaissance Technologies, LLC | 0.69% | 91.41K | $166.36K |
| 8 | Geode Capital Management, LLC | 0.68% | 90.35K | $164.44K |
| 9 | Morgan Stanley | 0.58% | 77.84K | $141.68K |
| 10 | Duncan Williams Asset Management, LLC | 0.47% | 63.24K | $115.10K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TVRD
TVRD Stock Rallies 149% So Far This Week: Here's What You Should Know - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxQUW5lN3RwSUlmUVNLQS1uOURfZHpfdF9Sd25tWklyMFVvbHdjR3BpWk9rUkUxNVJhSjNhSzlQR1BfNXBpQkZENVVJdG5lVFpPeWlkcUFPUTZCam9BUC1scmNzQ1Jnc1J5WjdsOWo0aGI5TEppcHYzUG14RExTOWFieGk4ZE9ncHR2TXltQU…
Why Tvardi Therapeutics (TVRD) Stock Is Up Today - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxOWU14N29aa1RKM3MwZ1JRQTVIVGJkMHIyOHg4Q2t4SExCOE5Fb1NSTWlmZnY2VjRfQXNhbWZGX0EtbGVlekdtMU5yNWdETm0xenJQeklCVVZTN3BVc01MOFRaMGNVR2Y0VHgzRTFiQjFPV28yVUdIVTRoR1BmWjNURm95RTJGc1hUWGFqMG…
TVRD Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTFBRV29pV0RoSEJXU1VCTHA3X3VTeE8xZGYxaEV3am82MjNLV3RYSG13dlV3NWZBTzdrNWtqMlRFY0pBNEtzUmRPY0phMnM5MmZoSFhjSDNjMzVxTW1tWTRwNnpLcmhYRVMteGxSeWVSRjRPSjlPNEktUldR?oc=5" target="_blank">TVR…
Raymond James upgrades Tvardi Therapeutics stock rating on Phase 1 data - Investing.com
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxQbFZSTVFRUFhBdzB2VDhFR2VHcklKM3hLNTE2XzB5eEY0bnRoaVpHSHRmSmR5NVM3czJvTFllcEVEbzNOd0diNndlbVRucDNFNHVkN2dTTUtJTDRORHFyaGhDMGh5ZFhWbXpncGxiQzNNOUdyY3NHc3JUNDE0TnI4SVVLMTROS1JIVld4aU…
Tvardi says TTI-109 matched exposure, cut diarrhea in phase 1 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxOVXlZd0FSRTdGVEZFRDdNM0lmbUJDdllXSWNLb3NPeGJDMVFNd3I1V0dQNHFoTi1EY3A5Rnp3bTY5V3o0eUcwR29maGFhLTQwd25iOGtjTEVJQmJFTk9SeGlDR0ZFdGRkQVdXZHVTdk8tZjFwcVowYmVNdy1sbUdUY2lGMXU2QTV5U3lSSz…
TVRD - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE1PSVhCWGtnWGN0UTl4OTRNY3UxRUYwM2c3OTlVVHRDaG9tYVNtVWstVnZNdFBvLW9wUkpOUXFWaC00UjRzZmc?oc=5" target="_blank">TVRD</a> <font color="#6f6f6f">Finviz</font>…
TVRD — Frequently Asked Questions
What is the current share price of Tvardi Therapeutics, Inc. (TVRD)?
As of 2026-09-07 16:24 PDT, Tvardi Therapeutics, Inc. (TVRD) trades at $1.84 on NasdaqCM. Its 52-week range is $1.50 to $42.98.
What is the market capitalisation of TVRD?
Tvardi Therapeutics, Inc. (TVRD) has a market capitalisation of $17.26M on NasdaqCM.
What is the P/E ratio of TVRD?
TVRD trades at a trailing price-to-earnings (P/E) ratio of -6.81. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 1.21.
What is the return on equity (ROE) of TVRD?
TVRD has a return on equity (ROE) of -86.96%. Its return on capital employed (ROCE) is -127.18%.
Is TVRD a good stock to buy?
This page provides a data-driven analysis of Tvardi Therapeutics, Inc. (TVRD), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.